Study on radiation dose of Cyberknife M6 stereotactic radiotherapy image guidance system
Jingsheng Wang,Xinyu Xu,Zhixiao Xue,Yang Dong,Xuyao Yu,Huaming Chen
DOI: https://doi.org/10.12354/j.issn.1000-8179.2023.20230634
2023-01-01
Chinese Journal of Clinical Oncology
Abstract:ObjectiveTo analyze the radiation dose and influencing factors generated by the Cyberknife M6 stereotactic radiotherapy image guided system and provide a reference for additional radiation doses in tumor patients undergoing M6 Cyberknife stereotactic radiotherapy treatment. MethodsA retrospective analysis was conducted on 216 tumor patients who underwent Cyberknife M6 stereotactic radiotherapy at Tianjin Medical University Cancer Institute & Hospital from January to May 2023. Patients were classified according to image guidance methods and treatment sites, irradiation dose, treatment segmentation times, and tube exposure parameters of the tumor target area. Total exposure times and cumulative irradiation dose were calculated, and the average irradiation times of different treatment sites were obtained. The average irradiation dose was compared with the irradiation dose of the tumor target area. The ROC curve was used to classify cutoff values for tumor volume and BED10, and multiple linear stepwise regression models were used to analyze factors influencing the cumulative dose. ResultsThe average exposure frequency, cumulative radiation dose (cGy), and cumulative radiation dose/target area radiation dose (%) of patients using 6D-skull (skull) tracking, x-sight (vertebral) tracking, synchronous breathing tracking, fiducial (gold standard) tracking, and x-sight lung tracking were 131 times, 1.6 cGy, 0.02%–0.18%; 212 times, 8.0 cGy, 0.05%–0.45%; 322 times, 12.2 cGy, 0.06%–0.62%; 237 times, 10.1 cGy, 0.07%–0.36%; and 411 times, 12 cGy, 0.20%–0.21%, respectively. The average exposure frequency, cumulative radiation dose (cGy), and cumulative radiation dose/target area radiation dose (%) of patients with brain, chest, abdomen, and pelvic tumors were 131 times, 1.6 cGy, and 0.02%–0.18%; 258 times, 9.6 cGy, 0.05%–0.62%; 191 times, 7.7 cGy, 0.08%–0.44%; and 209 times, 8.5 cGy, 0.07%–0.36%, respectively. The ROC curve was classified according to tumor volume (cutoff value 30 mL) and BED10 (cutoff value 60 Gy). Moreover, the cumulative radiation dose was influenced by the BED10 target area volume, target area volume, and tumor site. The cumulative dose was higher when tumor volume was≥30 mL, BED10>60 Gy, and tumors were located in the chest, abdomen, or pelvic cavity. ConclusionsThe 6D-skull tracking method provided the lowest average exposure frequency and cumulative radiation dose for patients with brain tumors. The average exposure frequency and cumulative radiation dose were similar for patients with chest, abdomen, and pelvic tumors corresponding to the other four image guidance methods. Hence, the Cyberknife M6 stereotactic radiotherapy system can verify the real-time position accuracy of patients during treatment, and the radiation dose received by patients through this system is relatively low.